Skip to main content

Advertisement

Table 3 The relationship between voriconazole initial drug levels and clinical and radiologic response to therapy at 6 and 12 weeks of follow-up

From: Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events

Variable Voriconazole level < 1.0 mg/L Voriconazole level ≥1.0 mg/L OR [95% CI] p-value
Intravenous maintenance dose administration 11 (35.4%) 26 (36.1%) 1.02 [0.39-2.77] 0.95
Voriconazole median dosage (mg) 280 (170–400) 255 (125–480) -- 0.61
Response to antifungal therapy at 6 weeks*     
Complete or partial response (n = 13) 7/13 (53.8%) 6/33 (18.2%) 0.19 [0.04-0.96] 0.03 §
Progression of disease (n = 9) 1/13 (7.7%) 8/33 (24.2%) 3.84 [0.42-184.3] 0.41 §
Response to antifungal therapy at 12 weeks*     
Complete or partial response (n = 22) 9/13 (69.2%) 13/33 (39.4%) 0.29 [0.05-1.34] 0.10 §
Progression of disease (n = 11) 3/13 (23.1%) 8/33 (24.2%) 1.07 [0.20-7.50] 1.00 §
Radiologic improvement*     
Pulmonary nodule resolution or decrease in size at 6 weeks (n = 46) 4 (30.8%) 13 (39.4%) 1.46 [0.32-7.83] 0.74 §
  1. * In patients with proven or probable invasive fungal disease (n = 46).
  2. † Chi-squared test.
  3. ‡ Two-sample t-test.
  4. § Fisher’s exact test.